RheumNow Live 2025

40 $

+ Include: 37 videos, size: 22.78 GB

+ Target Audience: rheumatologists and clinical immunologists

Description

+ Include: 37 videos, size: 22.78 GB

+ Target Audience: rheumatologists and clinical immunologists

+ Sample video: contact me for sample video

+ Information:

1. Overview

The RheumNow Live 2025 course provides an expert-led clinical update on the latest therapeutic advancements and practical challenges in rheumatology. The program covers emerging biologics, imaging guidelines, and management strategies for complex conditions including rheumatoid arthritis, psoriatic arthritis, spondyloarthritis, lupus, and vasculitis, with a strong focus on integrating new agents like JAK and TYK2 inhibitors into daily practice.

Course Date: 2025

2. Learning Objectives

  • Evaluate the efficacy, safety, and clinical positioning of new biologic therapies, JAK inhibitors, and TYK2 inhibitors across various rheumatic diseases.

  • Implement advanced imaging techniques for the accurate evaluation and ongoing monitoring of spondyloarthritis and vasculitis.

  • Develop comprehensive management plans for rheumatoid arthritis, addressing disease flares, multimorbidity, and the unique considerations for older adults.

  • Assess aggressive treatment strategies in psoriasis to prevent psoriatic arthritis and analyze head-to-head clinical studies for optimal biologic selection.

  • Apply updated clinical guidelines for managing complex conditions like systemic lupus erythematosus (SLE), including new steroid protocols and the role of interferons.

3. Target Audience

Best for rheumatologists and clinical immunologists who want updates on biologic therapies, JAK inhibitors, RA multimorbidity, and vasculitis.

4. Topics

  1. Adjourn

  2. Advances in Treatment of Spondyloarthritis

  3. AI applied to Rheumatoid Arthritis Care Practically Not Perfect

  4. BIMZELX bimekizumab-bkzx Expert Perspectives on a New Treatment for PsA nr-axSpA and AS by Dr Evan Siegel

  5. Can Aggressive Treatment of Psoriasis Prevent PsA

  6. Combination Biologic Therapies in PsA

  7. Dermatomyositis Updates Insights and JAK-Is too

  8. Head-to-head Studies in Psoriatic Disease What have we learned

  9. Imaging Evaluation of Spondyloarthritis

  10. Imaging in Vasculitis

  11. Interferons Role in SLE

  12. JAK Faculty Panel Discussion with QA

  13. JAK Inhibitors – POD III

  14. Key Considerations Managing Older Adults with RA

  15. KEYNOTE LECTURE Reinventing Oneself in Medicine

  16. Management of EGPA in 2025 and Beyond

  17. Modern Treatment of PMR

  18. Multimorbidity in RA What to Do and Who Should Do It

  19. Optimizing Care for PMR Advances and Challenges in Diagnosis and Treatment by Adam Brown MD Rheumatologist at C…

  20. POD 7 Spondyloarthritis

  21. POD I – Rheumatoid Arthritis

  22. POD V Vasculitis

  23. Progress in Hidradenitis Supprativa

  24. Psoriatic Arthritis – POD II

  25. Psoriatic Faculty Panel Discussion with QA

  26. Rheumatoid Faculty Panel Discussion with QA

  27. Spondyloarthritis Faculty Panel Discussion with QA

  28. STEP Environmental Rheumatology

  29. STEP Flares of Rheumatoid Arthritis

  30. STEP Morphea and Linear Scleroderma

  31. STEP New Steroid Rules for Lupus

  32. STEP Oral Surveillance 3 years later

  33. STEP Performance Art and Medicine

  34. TYK2 Inhibitors Where do they fit

  35. Vasculitis Faculty Panel Discussion with QA

  36. Welcome Introductions

  37. When JAKs Go Generic

Reviews

There are no reviews yet.

Be the first to review “RheumNow Live 2025”

Your email address will not be published. Required fields are marked *

36 − = 29
Powered by MathCaptcha